5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Abstract

Migraine is a debilitating disorder of the CNS. Although therapeutic options for migraine attacks have tremendously advanced with the development of triptans more than a decade ago, several conditions (such as vascular disease) restrict their use. Moreover, some patients do not respond to triptans and other currently available medications. Therefore, treatment alternatives are needed. Study data show that 5-HT(1F) receptor agonists successfully abort migraine attacks. These data also suggest a favorable vascular side-effect profile of these substances, which could be beneficial for migraine treatment in subjects with cardiac or vascular disease. We discuss the current knowledge of 5-HT(1F) receptor-mediated effects, in part by comparing them to triptans, and we also summarize data from basic research and clinical trials.

• Authors: Lars Neeb, Jannis Meents, Uwe Reuter
• Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (Neurotherapeutics) Vol. 7 Issue 2 Pg. 176-82 (Apr 2010) ISSN: 1878-7479 [Electronic] United States
• PMID: 20430316 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.

Chemical References

• 4-fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamide
• Benzamides
• Indoles
• Proto-Oncogene Proteins c-fos
• Receptors, Serotonin
• Serotonin Receptor Agonists
• Tryptamines
• serotonin 1F receptor

Topics

• Benzamides (therapeutic use)
• Gene Expression Regulation (drug effects)
• Humans
• Indoles (therapeutic use)
• Migraine Disorders (drug therapy, metabolism)
• Neurogenic Inflammation (drug therapy)
• Proto-Oncogene Proteins c-fos (metabolism)
• Receptors, Serotonin (metabolism)
• Serotonin Receptor Agonists (therapeutic use)
• Trigeminal Nuclei (drug effects, metabolism)
• Tryptamines (therapeutic use)